Population pharmacokinetic analysis of a nevirapine-based hiv-1 prevention of mother-to-child transmission program in uganda to assess the impact of different dosing regimens for newborns

Journal of Clinical Pharmacology

Volumn 53, Issue 3, 2013, Pages 294-304

  Frank, Monika ^a,b   Harms, Gundel ^c   Kunz, Andrea ^c   Kloft, Charlotte ^a,b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Nevirapine; Newborn dosing; Plasma placenta transfer; Population pharmacokinetics; Prevention of mother tochild transmission of HIV 1

Indexed keywords

NEVIRAPINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; BREAST FEEDING; BREAST MILK; COMPARTMENT MODEL; DELIVERY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; NEWBORN; PREGNANCY; UGANDA; VERTICAL TRANSMISSION;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; MILK, HUMAN; MODELS, BIOLOGICAL; NEVIRAPINE; PREGNANCY; UGANDA; YOUNG ADULT;

EID: 84877872945     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270012448397     Document Type: Article

References (33)

1. World Health Organization. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants: Recommendations for a Public Health Approach. http://whqlibdoc.who.int/publications/2010/9789241599818-eng. pdf. Updated October 18, 2010. Accessed October 30, 2011.
2. De Cock KM, Fowler MG, Mercier E, et al. Prevention of motherto-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA. 2000;283(9):1175-1182.
3. Tramontano E, Cheng YC. HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587. Biochem Pharmacol. 1992;43(6):1371-1376.
4. Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis. 1998;178(2):368-374.
5. Kunz A, Frank M, Mugenyi K, et al. Persistence of nevirapine in breast milk and plasma of mothers and their children after singledose administration. J Antimicrob Chemother. 2009;63(1):170-177. doi:10.1093/jac/dkn441.
6. Zisowsky J, Krause A, Dingemanse J. Drug development for pediatric populations: regulatory aspects. Pharmaceutics. 2010;2(4): 364-388.
7. Klassen TP, Hartling L, Craig JC, Offringa M. Children are not just small adults: the urgent need for high-quality trial evidence in children. PLoS Med. 2008;5(8):e172. doi:10.1371/journal .pmed.0050172.
8. Stocker H, Kruse G, Kreckel P, et al. Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004;48(11):4148-4153. doi:10.1128/AAC.48.11.4148-4153.2004.
9. Food and Drug Administration (FDA). Guidance for Industry: Bioanalytical Method Validation. www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf. Accessed October 30, 2011.
10. Jonsson EN, Karlsson MO. Automated covariate model building within NONMEM. Pharm Res. 1998;15(9):1463-1468.
11. Bonate PL. Pharmacokinetic-Pharmacodynamic Modeling and Simulation. New York: Springer; 2006. http://www.gbv.de/dms/bs/toc/504872532.pdf
12. Brendel K, Dartois C, Comets E, et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet. 2007;46(3):221-234.
13. Holford N. Model evaluation, visual predictive checks [PAGE 2008, Marseille]. http://www.page-meeting.org/pdf-assets/8694-Karlsson-Holford-VPC- Tutorial-hires.pdf. Updated August 19, 2008. Accessed January 31, 2011.
14. De Maat MM, Huitema AD, Mulder JW, Meenhorst PL, van Gorp EC, Beijnen JH. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br J Clin Pharmacol. 2002;54(4):378-385.
15. Mangesi L, Dowswell T. Treatments for breast engorgement during lactation. Cochrane Database Syst Rev. 2010;(9):CD006946. doi:10.1002/14651858. CD006946.pub2.
16. Kappelhoff BS, van Leth F, MacGregor TR, Lange J, Beijnen JH, Huitema AD. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther. 2005;10(1): 145-155.
17. UNAIDS. UNAIDS Global Report on the Global AIDS Epidemic 2010. http://www.unaids.org/globalreport/Global-report.htm
18. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med. 2010;363(16):1510- 1520. doi:10.1056/NEJMoa1000931.
19. AIDSinfo. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. http://aidsinfo.nih.gov/ contentfiles/PerinatalGL.pdf
20. Food and Drug Administration. Guidance for Industry: Population Pharmacokinetics. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072137.pdf. Accessed December 15, 2010.
21. Benaboud S, Ekouevi DK, Urien S, et al. Population pharmacokinetics of nevirapine in HIV-1 infected pregnant women and their neonates (ANRS 12109). Antimicrob Agents Chemother. 2011;55(1):331-337. doi:10.1128/AAC.00631-10.
22. Elsherbiny D, Cohen K, Jansson B, Smith P, McIlleron H, Simonsson US. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV-and tuberculosis-infected South African patients. Eur J Clin Pharmacol. 2009;65(1):71-80. doi:10.1007/s00228-008-0481-y.
23. Cressey TR, Jourdain G, Lallemant MJ, et al. Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr. 2005;38(3):283-288.
24. Capparelli EV, Aweeka F, Hitti J, et al. Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. HIV Med. 2008;9(4):214-220. doi:10.1111/j.1468-1293.2008.00553.x.
25. Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS. 1999;13(4):479-486.
26. Muro E, Droste JA, Hofstede HT, Bosch M, Dolmans W, Burger DM. Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies. J Acquir Immune Defic Syndr. 2005;39(4):419-421.
27. Mirochnick M, Dorenbaum A, Blanchard S, et al. Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. J Acquir Immune Defic Syndr. 2003;33(2):153-156.
28. Natarajan U, Pym A, McDonald C, et al. Safety of nevirapine in pregnancy. HIV Med. 2007;8(1):64-69. doi:10.1111/j.1468-1293.2007.00433.x.
29. Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2007;(1):CD003510. doi:10.1002/14651858.CD003510. pub2.
30. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354(9181):795-802. doi:10.1016/S0140-6736(99)80008-7.
31. Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther. 1998;20(6):1071-1092.
32. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 2003;187(5):725-735. doi:10.1086/367898.
33. Jackson JB, Becker-Pergola G, Guay LA, et al. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS. 2000;14(11):F111-F115.